NCT05838170View on ClinicalTrials.gov

Study of TP-04 in Participants With Papulopustular Rosacea

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

November 13, 2023

Study Completion Date

November 13, 2023

Conditions
Papulopustular Rosacea
Interventions
DRUG

Lotilaner Gel, 2.0%

Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).

OTHER

Vehicle control gel

Aqueous gel

Trial Locations (5)

L6J 7W5

The Centre for Clinical Trials, Oakville

K9J 5K2

SKiN Centre for Dermatology, Peterborough

N2J 1C4

K. Papp Clinical Research, Waterloo

H2X 2V1

Innovaderm Research Inc., Montreal

G1W4R4

Centre de Recherche Saint-Louis, Québec

All Listed Sponsors
lead

Tarsus Pharmaceuticals, Inc.

INDUSTRY